公开(公告)号：US20100286055A1

公开(公告)日：2010-11-11

申请号：US12527185

申请日：2008-02-14

Applicant: Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

Inventor： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

IPC: A61K38/17 ,  A61P17/02

CPC classification number: A61K38/17

Abstract: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for accelerating wound healing. Also provided is a method of accelerating wound healing, the method comprising providing a therapeutically effective amount of WNT3 A, or a therapeutically effective fragment or derivative thereof, to a site where wound healing is to be accelerated. The medicaments and methods of the invention may be of particular use in accelerating the healing of skin wounds.

Abstract translation: 提供用作加速伤口愈合的药物的WNT3A或其治疗有效的片段或衍生物。 还提供了加速伤口愈合的方法，该方法包括向受伤愈合加速的部位提供治疗有效量的WNT3A或其治疗有效的片段或衍生物。 本发明的药物和方法可以特别用于加速皮肤伤口的愈合。

公开(公告)号：US20080153795A1

公开(公告)日：2008-06-26

申请号：US11723193

申请日：2007-03-16

Applicant: Nick Occleston ,  Kerry Nield ,  Sharon O'Kane ,  Mark Ferguson

Inventor： Nick Occleston ,  Kerry Nield ,  Sharon O'Kane ,  Mark Ferguson

IPC: A61K31/56 ,  A61P17/02

CPC classification number: A61K31/56

Abstract: The present invention relates to the manufacture of medicaments for accelerating the healing of wounds. The invention also relates to methods of treatment for accelerating the healing of wounds. In particular the invention relates to medicaments and methods for the acceleration of healing of skin wounds. The invention relates to wound dressings that are able to provide active agents to a wound, and thereby accelerate healing of the wound, and to formulations such as creams or sprays that may be used to accelerate healing.

Abstract translation: 本发明涉及用于加速伤口愈合的药物的制造。 本发明还涉及用于加速伤口愈合的治疗方法。 特别地，本发明涉及用于加速皮肤伤口愈合的药物和方法。 本发明涉及能够向伤口提供活性剂，从而加速伤口愈合的伤口敷料以及可用于加速愈合的制剂如霜剂或喷雾剂。

公开(公告)号：US20080153796A1

公开(公告)日：2008-06-26

申请号：US11723194

申请日：2007-03-16

Applicant: Nick Occleston ,  Kerry Nield ,  Sharon O'Kane ,  Mark Ferguson

Inventor： Nick Occleston ,  Kerry Nield ,  Sharon O'Kane ,  Mark Ferguson

IPC: A61K31/56 ,  A61P17/02

CPC classification number: A61K31/56

Abstract: The present invention relates to medicaments and methods for promoting wound contraction. In certain embodiments the invention provides medicaments and methods capable of promoting wound contraction without acceleration of re-epithelialisation.

Abstract translation: 本发明涉及用于促进伤口收缩的药物和方法。 在某些实施方案中，本发明提供能够促进伤口收缩而不加速再上皮化的药物和方法。

公开(公告)号：US20100144690A1

公开(公告)日：2010-06-10

申请号：US12520496

申请日：2007-12-23

Applicant: Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

Inventor： Mark W. J. Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

IPC: A61K31/57 ,  A61K31/575 ,  A61P17/02

CPC classification number: A61K31/57 ,  A61K31/575 ,  A61K31/58

Abstract: Provided are antagonists of FXR activity for use as medicament for the prevention, reduction or inhibition of scarring. This use may preferably be to prevent, reduce or inhibit scarring formed on healing of wounds. The invention also provides corresponding methods of treatment. Preferred antagonists of FXR activity include guggulsterone (Z); guggulsterone (E); a scalarane; 80-574; and a 5α-bile alcohol. In advantageous embodiments, up to 32 μM of the antagonist of FXR activity may be provided per linear cm of wound, or cm2 of a wound or fibrotic disorder, over a 24 hour period in order to inhibit scarring.

Abstract translation: 提供FXR活性的拮抗剂，用作预防，减少或抑制瘢痕形成的药物。 该用途可以优选地是防止，减少或抑制伤口愈合时形成的瘢痕形成。 本发明还提供相应的治疗方法。 优选的FXR活性拮抗剂包括苦瓜酮（Z）; 格鲁斯酮（E）; 一个标准 80-574; 和5α-胆汁醇。 在有利的实施方案中，为了抑制瘢痕形成，可以在24小时内每线性cm伤口或cm2的伤口或纤维化病症提供高达32μM的FXR活性拮抗剂。

公开(公告)号：US20110082171A1

公开(公告)日：2011-04-07

申请号：US12995900

申请日：2009-06-02

Applicant: Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nick Goldspink

Inventor： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nick Goldspink

IPC: A61K31/437 ,  A61P17/02

CPC classification number: A61K31/437

Abstract: Provided is the use of an agonist of a GABAA receptor for use in the prevention, reduction or inhibition of scarring formed on healing of a wound. Also provided is a method of preventing, reducing or inhibiting scarring formed on healing of a wound, in which a therapeutically effective amount of an agonist of a GABAA receptor is administered to a patient in need of such prevention, reduction or inhibition. The GABAA receptor agonist used may be an agonist specific to the GABAA receptor, such as Gaboxadol (7-tetra hydroisoxazolo[5,4-c]pyridin-3-ol), or a pharmaceutically acceptable salt thereof. The scarring to be prevented, reduced or inhibited may be scarring formed on healing of a wound of the dermis.

Abstract translation: 提供了用于预防，减少或抑制伤口愈合时形成的瘢痕形成的GABA A受体激动剂的用途。 还提供了预防，减少或抑制伤口愈合时形成的瘢痕形成的方法，其中向需要这种预防，减少或抑制的患者施用治疗有效量的GABA A受体激动剂。 所使用的GABA A受体激动剂可以是对GABA A受体特异的激动剂，例如加波沙朵（7-四氢异恶唑并[5,4-c]吡啶-3-醇））或其药学上可接受的盐。 要防止，减少或抑制的疤痕可能在真皮的伤口愈合时形成瘢痕。

公开(公告)号：US20100261659A1

公开(公告)日：2010-10-14

申请号：US12596332

申请日：2008-04-17

Applicant: Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

Inventor： Mark W. J. Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

IPC: A61K38/17 ,  A61P17/02

CPC classification number: A61K38/177

Abstract: Provided is secreted Frizzled Related Protein 3 (sFRP3), or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. The scarring may be associated with the healing of a wound, or with a fibrotic disorder. The scarring may be associated with surgical wounds. The scarring may be scarring of the skin. The medicament may be a topical medicament, and may be suitable for local injection. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of sFRP3, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition.

Abstract translation: 提供分泌的卷曲相关蛋白3（sFRP3）或其治疗有效的片段或衍生物，用作预防，减少或抑制瘢痕形成的药物。 瘢痕形成可能与伤口愈合或纤维化疾病有关。 瘢痕形成可能与外科伤口有关。 瘢痕可能是皮肤疤痕。 药物可以是局部药物，并且可以适用于局部注射。 还提供了预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，减少或抑制的患者施用治疗有效量的sFRP3或其治疗有效的片段或衍生物。

公开(公告)号：US20100204248A1

公开(公告)日：2010-08-12

申请号：US12671005

申请日：2008-07-31

Applicant: Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

Inventor： Mark William James Ferguson ,  Nicholas Occleston ,  Sharon O'Kane ,  Nicholas Goldspink ,  Kerry Nield

IPC: A61K31/52 ,  C07D473/38 ,  A61P17/02

CPC classification number: A61K31/407 ,  A61K31/52

Abstract: Provided is the use of an agonist of a member of the nuclear hormone receptor NR4A subgroup in the manufacture of a medicament for the prevention, reduction or inhibition of scarring in a non-ocular tissue. Also provided is a method of preventing, reducing or inhibiting scarring in a non-ocular tissue, the method comprising administering a therapeutically effective amount of an agonist of a member of the nuclear hormone receptor NR4A subgroup to a patient in need of such prevention, reduction or inhibition. The NR4A agonist may be 6-mercaptopurine. The medicaments and methods may preferably be used to prevent, reduce or inhibit scarring in the skin. The medicaments and methods of the invention may be used to accelerate healing of wounds.

Abstract translation: 提供了核激素受体NR4A亚组的成员的激动剂在制备用于预防，减少或抑制非眼组织中的瘢痕形成的药物中的用途。 还提供了一种在非眼组织中预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，还原的患者施用治疗有效量的激素受体NR4A亚组成员的激动剂 或抑制。 NR4A激动剂可以是6-巯基嘌呤。 药物和方法可优选用于预防，减少或抑制皮肤中的瘢痕形成。 本发明的药物和方法可用于加速伤口愈合。

公开(公告)号：US20100137201A1

公开(公告)日：2010-06-03

申请号：US12306501

申请日：2007-06-29

Applicant: Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

Inventor： Mark W. J. Ferguson ,  Hugh G. Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield ,  Nicholas Goldspink

IPC: A61K38/17 ,  C07K14/435

CPC classification number: A61K38/1709

Abstract: There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

Abstract translation: 提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防，减少或抑制瘢痕形成的药物中的用途。 还提供了WNT5A或其治疗有效的片段或衍生物在制备用于预防和/或治疗纤维化病症的药物中的用途。 另外的方面涉及可以预防，减少或抑制瘢痕形成的方法，以及可以通过哪些可以预防和/或治疗纤维化疾病。 还提供了可用于本发明的药物或方法中的治疗有效量的WNT5A或其片段或衍生物。

公开(公告)号：US20120071425A1

公开(公告)日：2012-03-22

申请号：US13322660

申请日：2010-06-10

Applicant: Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Kerry Nield ,  Tracey Mason ,  James Bush ,  Julian Hanak

Inventor： Mark William James Ferguson ,  Sharon O'Kane ,  Nicholas Occleston ,  Kerry Nield ,  Tracey Mason ,  James Bush ,  Julian Hanak

IPC: A61K8/60 ,  A61Q19/00 ,  A61P17/00 ,  C07H11/04 ,  A61K31/7024

CPC classification number: A61K8/60 ,  A61Q17/005 ,  A61Q19/10

Abstract: There is provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, for providing and/or maintaining a consistent skin colour, particularly to reducing redness of skin. There is also provided the use of mannose-6-phosphate, or a salt, precursor or analogue thereof, as a skin improvement agent for providing a cosmetic effect and mannose-6-phosphate, or a salt, precursor or analogue thereof, for use in treating normal or damaged skin, wherein damaged skin is skin that has been subject to epidermal and/or dermal damage.

Abstract translation: 提供了甘露糖-6-磷酸酯或其盐，前体或类似物用于提供和/或维持一致的皮肤颜色，特别是减少皮肤发红的用途。 还提供了使用甘露糖-6-磷酸酯或其盐，前体或类似物作为提供化妆效果的皮肤改善剂和甘露糖-6-磷酸或其盐，前体或类似物，以供使用 在治疗正常或损伤的皮肤中，其中损伤的皮肤是经受表皮和/或皮肤损伤的皮肤。

公开(公告)号：US20110212897A1

公开(公告)日：2011-09-01

申请号：US12527182

申请日：2008-02-14

Applicant: Mark William James Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

Inventor： Mark William James Ferguson ,  Hugh Laverty ,  Nicholas Occleston ,  Sharon O'Kane ,  Kerry Nield

IPC: C07K14/435 ,  A61K38/17 ,  A61P17/02

CPC classification number: A61K38/1709

Abstract: Provided is WNT3A, or a therapeutically effective fragment or derivative thereof, for use as a medicament for the prevention, reduction or inhibition of scarring. Also provided is a method of preventing, reducing or inhibiting scarring, the method comprising administering a therapeutically effective amount of WNT3A, or a therapeutically effective fragment or derivative thereof, to a patient in need of such prevention, reduction or inhibition. The methods and medicaments of the invention are suitable for use in the prevention, reduction or inhibition of scarring arising as a result of healing of a wound, or scarring associated with a fibrotic disorder. The methods and medicaments disclosed are of particular use in preventing, reducing or inhibiting scarring of the skin.

Abstract translation: 提供用作预防，减少或抑制瘢痕形成的药物的WNT3A或其治疗有效的片段或衍生物。 还提供了预防，减少或抑制瘢痕形成的方法，所述方法包括向需要这种预防，减少或抑制的患者施用治疗有效量的WNT3A或其治疗有效的片段或衍生物。 本发明的方法和药物适用于预防，减少或抑制由于伤口愈合或与纤维化病症相关的瘢痕形成引起的瘢痕形成。 所公开的方法和药物特别用于预防，减少或抑制皮肤瘢痕形成。